Amine salts of a CRTH2 antagonist
AssigneeActimis Pharmaceuticals, Inc.
InventorTai Wei Ly
Life of this patent
Estimating the term…
Abstract
Provided are amine salts of {4,6-bis(dimethylamino)-2-(4-(4-(trifluoromethyl)benzamido)benzyl)pyrimidin-5-yl}-acetic acid, processes for their preparation, pharmaceutical compositions containing them, and their use for treating, preventing, or ameliorating one or more symptoms of a CRTH2-mediated disorder or disease.
Claims39
A salt in a crystalline form, comprising ethylenediamine and {4,6-bis(dimethylamino)-2-(4-(4-(trifluoromethyl)benzamido)benzyl)pyrimidin-5-yl} acetic acid of Formula I:
- wherein the crystalline form has an X-ray powder diffraction pattern with a peak expressed in two-theta at approximately 5.9°, 11.6°, 17.5° and 29.4°.
A salt in a crystalline form, comprising piperazine and {4,6-bis(dimethylamino)-2-(4-(4-(trifluoromethyl)benzamido)benzyl)pyrimidin-5-yl}acetic acid of Formula I:
- wherein the crystalline form has an X-ray powder diffraction pattern with a peak expressed in two-theta at approximately 10.7, 15.9, 22.3, or 24.0°.
A salt in a crystalline form, comprising benzathine and {4,6-bis(dimethylamino)-2-(4-(4-(trifluoromethyl)benzamido)benzyl)pyrimidin-5-yl}acetic acid of Formula I:
- wherein the crystalline form has an X-ray powder diffraction pattern with a peak expressed in two-theta at approximately 8.0, 11.5, 16.0, 17.5, or 23.4°.
A salt in a crystalline form, comprising choline and {4,6-bis(dimethylamino)-2-(4-(4-(trifluoromethyl)benzamido)benzyl)pyrimidin-5-yl}acetic acid of Formula I:
- wherein the crystalline form has an X-ray powder diffraction pattern with a peak expressed in two-theta at approximately 6.5, 19.6, 20.0, 21.9, or 26.1°.
Dependencies are inferred from the claim text.